GLSI - Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates

Greenwich LifeSciences (GLSI) entered into an option agreement with Texas based, Westport Bio to in-license a pre-clinical coronavirus vaccine program that is currently at the stage of pre-clinical animal testing.In exchange for the option, the Company has agreed to sponsor research in an aggregate amount of up to $250K plus additional license and assignment fees. Westport Bio’s coronavirus vaccine program includes up to 7 vaccine candidates which are designed to complement or improve upon the DNA/RNA based coronavirus vaccines that are in advanced Phase III clinical trials or that have recently been approved by the FDA for emergency use.Westport Bio is focused on multi-antigen vaccine technology. The founder of Westport Bio is Snehal Patel, CEO of Greenwich LifeSciences.Shares are up 1.9% PM.

For further details see:

Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates